Studiene/artiklene som er nevnt i SPC-teksten:
Studie 1:
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial Stewart Tepper, Messoud Ashina, Uwe Reuter, Jan L Brandes, David Doležil, Stephen Silberstein, Paul Winner, Dean Leonardi, Daniel Mikol, Robert Lenz Lancet Neurol 2017; 16: 425–34 https://doi.org/10.1016/S1474-4422(17)30083-2
Studie 2:
A Controlled Trial of Erenumab for Episodic Migraine Peter J. Goadsby, M.D., Ph.D., Uwe Reuter, M.D., Yngve Hallstrom, M.D., Gregor Broessner, M.D., Jo H. Bonner, M.D., Feng Zhang, M.S., Sandhya Sapra, Ph.D., Hernan Picard, M.D., Ph.D., Daniel D. Mikol, M.D., Ph.D., and Robert A. Lenz, M.D., Ph.D. N Engl J Med 2017;377:2123-32. https://www.nejm.org/doi/full/10.1056/NEJMoa1705848
Langvarig oppfølgingsstudie:
Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial Messoud Ashina, Peter J. Goadsby, Uwe Reuter, Stephen Silberstein, David W. Dodick, Fei Xue, Feng Zhang, Gabriel Paiva da Silva Lima, Sunfa Cheng, Daniel D. Mikol European journal of neurology , 2021, Vol.28(5), p.1716-1725 https://doi.org/10.1111/ene.14715
Studie 3:
Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2–4 Prior Preventive Treatments Had Failed LIBERTY 3-Year Study Uwe Reuter, MD, Peter J. Goadsby, MD, Michel D. Ferrari, MD, Gabriel Paiva Da Silva Lima, MD, Subhayan Mondal, MStat, Jawed Kalim, MD, Fatima Hasan, PhD, Shihua Wen, PhD, Michal Arkuszewski, MD, Shaloo Pandhi, MD, Tracy Stites, PhD, and Michel Lanteri-Minet, MD Neurology 2024;102:e209349. https://www.neurology.org/doi/10.1212/WNL.0000000000209349
Studie 4:
Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial Uwe Reuter, Marc Ehrlich, Astrid Gendolla, Axel Heinze, Jan Klatt, Shihua Wen, Peggy Hours-Zesiger, Jacqueline Nickisch, Christian Sieder, Christian Hentschke and Monika Maier-Peuschel Cephalalgia 2022, Vol. 42(2) 108–118 https://journals.sagepub.com/doi/10.1177/03331024211053571